Assembly Biosciences’ (ASMB) Neutral Rating Reiterated at HC Wainwright

Assembly Biosciences (NASDAQ:ASMB)‘s stock had its “neutral” rating reiterated by equities research analysts at HC Wainwright in a research report issued on Monday,Benzinga reports.

Assembly Biosciences Stock Up 3.0 %

NASDAQ ASMB opened at $11.01 on Monday. The company’s 50 day moving average is $12.91 and its 200-day moving average is $15.13. Assembly Biosciences has a 12-month low of $10.27 and a 12-month high of $19.93. The firm has a market cap of $69.98 million, a P/E ratio of -1.64 and a beta of 0.62.

Assembly Biosciences (NASDAQ:ASMB) last posted its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($1.57) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.75) by $0.18. The business had revenue of $7.36 million for the quarter, compared to analyst estimates of $7.05 million. Assembly Biosciences had a negative net margin of 144.05% and a negative return on equity of 121.46%. Equities analysts expect that Assembly Biosciences will post -6.87 EPS for the current year.

Insider Buying and Selling

In other news, Director Michael Houghton bought 3,202 shares of the firm’s stock in a transaction that occurred on Monday, December 30th. The shares were acquired at an average price of $15.61 per share, with a total value of $49,983.22. Following the acquisition, the director now owns 3,202 shares of the company’s stock, valued at approximately $49,983.22. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. 5.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Assembly Biosciences

A number of institutional investors have recently made changes to their positions in the stock. Marshall Wace LLP increased its holdings in shares of Assembly Biosciences by 16.5% in the 4th quarter. Marshall Wace LLP now owns 14,823 shares of the biopharmaceutical company’s stock worth $234,000 after buying an additional 2,098 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Assembly Biosciences by 5,137.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 3,509 shares of the biopharmaceutical company’s stock worth $53,000 after buying an additional 3,442 shares during the last quarter. FMR LLC increased its holdings in shares of Assembly Biosciences by 29.7% in the 3rd quarter. FMR LLC now owns 15,855 shares of the biopharmaceutical company’s stock worth $240,000 after buying an additional 3,635 shares during the last quarter. Palumbo Wealth Management LLC bought a new position in shares of Assembly Biosciences in the 4th quarter worth $180,000. Finally, Man Group plc bought a new position in shares of Assembly Biosciences in the 4th quarter worth $309,000. Institutional investors own 19.92% of the company’s stock.

About Assembly Biosciences

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.